<DOC>
	<DOCNO>NCT00334854</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , ifosfamide doxorubicin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Radiation therapy use high-energy x-ray kill tumor cell . Giving combination chemotherapy without radiation therapy surgery may make tumor small reduce amount normal tissue need remove . Giving radiation therapy surgery may kill tumor cell remain surgery . PURPOSE : This phase III trial study well give ifosfamide doxorubicin , radiation therapy , and/or surgery work treat young patient localized soft tissue sarcoma .</brief_summary>
	<brief_title>Ifosfamide Doxorubicin , Radiation Therapy , and/or Surgery Treating Young Patients With Localized Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine survival rate ( event-free survival overall survival [ OS ] ) pattern treatment failure patient synovial sarcoma adult-type soft tissue sarcoma treat ifosfamide doxorubicin hydrochloride , radiotherapy , and/or surgery . - Determine role ifosfamide doxorubicin hydrochloride improve response rate patient unresectable synovial sarcoma adult-type soft tissue sarcoma . Secondary - Evaluate clinical/pathological prognostic factor , particularly tumor grade radiological pathological response neoadjuvant treatment . - Determine impact omit adjuvant chemotherapy patient low-risk synovial sarcoma ( tumor &lt; 5 cm ) . - Determine role adjuvant chemotherapy improve metastases-free survival OS patient adult-type soft tissue sarcoma ( Intergroup Rhabdomyosarcoma Study [ IRS ] postsurgical grouping system I-II , tumor grade 3 , tumor size &gt; 5 cm ) . OUTLINE : This nonrandomized , prospective , historically control , multicenter study . Patients synovial sarcoma stratify accord Intergroup Rhabdomyosarcoma Study ( IRS ) postsurgical group system ( I vs II v III ) tumor size ( ≤ 5 cm v &gt; 5 cm ) . Patients adult-type soft tissue sarcoma stratify accord IRS postsurgical grouping system ( I vs II v III ) , tumor size ( ≤ 5 cm v &gt; 5 cm ) , tumor grade ( G1 vs G2 v G3 ) . Patients assign 1 9 treatment group accord disease stratification . Synovial sarcoma - Group 1 ( IRS group I , tumor ≤ 5 cm ) : Patients undergo surgical resection tumor . - Group 2 ( IRS group I , tumor &gt; 5 cm ) : Patients receive ifosfamide IV 3 hour day 1-3 doxorubicin hydrochloride IV 4-6 hour day 1 2 ( IFO-DOX ) . Treatment repeat every 21 day 4 course . - Group 3 ( IRS group II , tumor ≤ 5 cm ) : Patients receive 3 course IFO-DOX . After completion chemotherapy , patient undergo radiotherapy 5 day week 5-6 week . - Group 4 ( IRS group II , tumor &gt; 5 cm ) : Patients receive 3 course IFO-DOX . Patients receive ifosfamide alone IV 3 hour day 1-3 . Treatment ifosfamide repeat every 21 day 2 course . Patients also receive concurrent radiotherapy ( concurrently ifosfamide ) 5 day week 5-6 week . After completion radiotherapy , patient receive 1 additional course IFO-DOX . - Group 5 ( IRS group III , N1 ) : Patients receive 3 course IFO-DOX . Patients response chemotherapy receive 1 follow local therapy : - Delayed complete resection* - Radiotherapy ( group 3 ) follow surgery* - Delayed complete resection* follow radiotherapy** ( group 3 ) - Delayed incomplete resection* follow radiotherapy** ( group 3 ) - Radiotherapy ( group 3 ) Patients major minor response chemotherapy receive 2 course ifosfamide concurrent radiotherapy follow 1 additional course IFO-DOX ( group 4 , ) . NOTE : * Patients undergo surgery 5 week completion chemotherapy and/or radiotherapy . NOTE : **Patients undergo radiotherapy begin &lt; 21 day surgery . Adult-type soft tissue sarcoma - Group 1 ( IRS group I , tumor ≤ 5 cm ) : Patients undergo surgical resection tumor . - Group 2 ( IRS group I , tumor &gt; 5 cm ) : Patients receive therapy accord tumor grade : - G1 disease : Patients undergo surgical resection . - G2 disease : Patients undergo radiotherapy 5 day week 5-6 week . - G3 disease : Patients receive follow sequential treatment : 3 course IFO-DOX follow 2 course ifosfamide concurrent radiotherapy follow 1 course IFO-DOX . - Group 3 ( IRS group II , N0 ) : Patients receive therapy accord tumor grade : - G1 disease : Patients undergo surgical resection . - G2-3 disease ( ≤ 5 cm ) G2 disease ( &gt; 5 cm ) : Patients undergo radiotherapy 5 day week 5-6 week . - G3 disease ( &gt; 5 cm ) : Patients undergo sequential treatment ( group 2 , adult-type soft tissue sarcoma ) . - Group 4 ( IRS group III , N1 ) : Patients receive 3 course IFO-DOX . Patients response chemotherapy receive local therapy ( group 5 synovial sarcoma ) . Patients major minor response chemotherapy receive 2 course ifosfamide concurrent radiotherapy follow 2 additional course IFO-DOX ( group 4 , synovial sarcoma ) . After completion study therapy , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 250 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm synovial sarcoma adulttype softtissue sarcoma Adulttype soft tissue sarcoma include follow : Fibrosarcoma ( adulttype ) No infantile fibrosarcoma Malignant peripheral nerve sheath tumor Malignant schwannoma Neurofibrosarcoma Epithelioid sarcoma Leiomyosarcoma Clear cell sarcoma Liposarcoma Alveolar softpart sarcoma Malignant fibrous histiocytoma Hemangiopericytoma Angiosarcoma Dermatofibrosarcoma protuberans Mesenchymal chondrosarcoma No borderline tumor ( e.g. , hemangioendothelioma ) No small round cell tumor ( e.g. , extraosseous Ewing 's sarcoma/primitive neuroectodermal tumor desmoplastic small round cell tumor ) Postirradiation softpart sarcoma allow Diagnostic surgery perform within past 8 week ( patient require adjuvant chemotherapy ) No evidence metastatic disease Involved locoregional lymph node allow PATIENT CHARACTERISTICS : No prior malignancy No preexisting illness preclude study treatment* Normal renal function ( nephrotoxicity grade 01 ) * No history cardiac disease* Normal shorten fraction ( &gt; 28 % ) * Ejection fraction &gt; 47 % * NOTE : * For patient require adjuvant chemotherapy PRIOR CONCURRENT THERAPY : No prior cancer treatment except primary surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>childhood synovial sarcoma</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>childhood alveolar soft-part sarcoma</keyword>
	<keyword>childhood angiosarcoma</keyword>
	<keyword>childhood epithelioid sarcoma</keyword>
	<keyword>childhood fibrosarcoma</keyword>
	<keyword>childhood leiomyosarcoma</keyword>
	<keyword>childhood liposarcoma</keyword>
	<keyword>childhood neurofibrosarcoma</keyword>
	<keyword>localize childhood malignant fibrous histiocytoma bone</keyword>
	<keyword>childhood malignant hemangiopericytoma</keyword>
	<keyword>dermatofibrosarcoma protuberans</keyword>
	<keyword>chondrosarcoma</keyword>
</DOC>